查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493227

ADHD（注意力不足過動症）市場規模、佔有率、趨勢分析報告：按藥物類型、人口統計、分銷管道、地區、細分市場預測，2024-2030 年

Attention Deficit Hyperactivity Disorder Market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Demographics (Children, Adults), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

ADHD（注意力不足過動症）市場成長與趨勢：

Grand View Research的最新報告顯示，到2030年，全球ADHD（注意力不足過動症）市場規模預計將達到186億美元。

預計 2024 年至 2030 年該市場將以 3.7% 的複合年成長率擴張。強大的產品平臺的存在以及多動症治療的後續核准預計將推動市場成長。後期管道包括Neurocentria, Inc.開發的NRCT-101、Supernus Pharmaceuticals, Inc.開發的SPN-812和大塚美國製藥公司開發的EB-1020。

政府機構正在採取的有關多動症早期診斷和治療的幾項舉措可能會支持市場成長。 2021 年 1 月，澳洲政府將 Vyvanse 納入治療成人 ADHD 的藥物福利計劃 (PBS)。透過此應用程式，Vyvanse 現在可以以補貼價格向患者提供服務，超過 20,000 名患者以較低的成本接受類似的治療。如果沒有 PBS 的津貼，患者每年將不得不支付超過 1,200 美元的治療費用。納入 PBS 後，治療費用為每次治療 41.30 美元。預計此類舉措也將推動市場成長。

患者、醫生和其他醫療保健提供者對 ADHD 的認知不斷提高，可能會增加對診斷和治療的需求，從而推動 ADHD（注意力不足過動症）市場的成長。 ADHD（注意力不足過動症）輔導組織 (ACO) 將 10 月定為 ADHD 意識月，旨在提高人們的認知，為研究和開發籌集資金，並對人們進行有關該疾病的教育。這項措施可以促進早期診斷並提高產品普及。

然而，患有多動症的兒童與其他精神疾病合併症的風險很高，這往往使診斷和治療變得複雜。根據靈北基金會 2021 年發布的一項研究，患有註意力不足過動症且患有其他精神疾病的人更有可能避免服藥。過動症兒童常見的合併症包括憂鬱症、焦慮症、躁鬱症、學習障礙、早期語言和溝通障礙以及對立障礙。

此外，缺乏治療過動症的興奮劑藥物迫使患者支付昂貴的品牌藥物，為行為療法等替代療法騰出空間，並對過動症藥物治療的需求產生負面影響。美國緝毒局 (DEA) 等監管機構實施了嚴格的法規，限制過動症藥物的生產，以避免誤用和濫用。隨著需求的增加，可能會出現藥物短缺，導致治療成本更高並限制市場成長。因此，藥品短缺可能會阻礙市場成長。

ADHD（注意力不足過動症）市場報告亮點

  • 按藥物類型分類，由於對這些藥物和症狀管理的高需求、政府對使用興奮劑藥物的支持以及針對ADHD（注意力不足過動症）的持續臨床試驗，興奮劑細分市場將在2023 年成為最大的市場。
  • 從人口統計來看，由於目標人口龐大且開拓ADHD（注意力不足過動症）的風險較高，2023 年 ADHD（注意力不足過動症）市場將由成人市場主導。據 ADD Health and Wellness Centers, Inc. 稱，這種疾病影響著大約 4% 到 5% 的成年人口。
  • 預計 2023 年 ADHD（注意力不足過動症）市場將在預測期內出現最快的成長，主要由市場細分領域主導。這是因為 ADHD（注意力不足過動症）藥物在零售藥局隨處可見，患者很容易取得。
  • 由於醫療保健專業人員對可用於治療的藥物的認知較高以及疾病盛行率上升等因素，北美在 2023 年將主導全球市場。據加拿大 ADHD 意識中心 (CADDAC) 稱，這種疾病影響加拿大超過 150 萬人。
  • 亞太地區預計將成為預測期內成長最快的地區，從而增加該地區過動症的盛行率和治療需求。例如，ADHD 是最常見的神經發育障礙之一，在澳大利亞，大約 8.2% 的兒童和 11% 的男孩被診斷出患有 ADHD。

目錄

第1章調查方法和範圍

第 2 章 第 2 章執行摘要

  • 市場展望
  • 分部展望
    • 藥品類型展望
    • 人口前景
    • 分銷通路展望
    • 區域展望
  • 競爭考察

第 3 章 ADHD（注意力不足過動症）市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • ADHD（注意力不足過動症）市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 ADHD（注意力不足過動症）市場：藥物類型的估計和趨勢分析

  • 2023 年和 2030 年按藥物類型分類的市場佔有率佔有率
  • 細分儀表板
  • 按藥物類型分類的全球過動症（注意力不足過動症）市場展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 精神興奮劑
  • 非精神興奮劑

第5章 ADHD（注意力不足過動症）市場：人口統計估計與趨勢分析

  • 2023 年和 2030 年按人口統計的市場佔有率
  • 細分儀表板
  • 全球 ADHD（注意力不足過動症）市場展望（按人口統計）
  • 2018-2030年市場規模、預測及趨勢分析
  • 孩子
  • 成人

第6章 ADHD（注意力不足過動症）市場：通路估計與趨勢分析

  • 2023 年及 2030 年分銷通路市場佔有率
  • 細分儀表板
  • 按分銷管道分類：全球 ADHD（注意力不足過動症）市場展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院藥房
  • 零售藥房

第7章 ADHD（注意力不足過動症）市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 8 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Pfizer, Inc.
    • Johnson &Johnson Services, Inc.
    • Lupin
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Mallinckrodt plc.
    • Purdue Pharma Lp
    • Supernus Pharmaceuticals, Inc.
    • NEOS Therapeutics, Inc.
    • HS Hospital Service SpA
Product Code: GVR-2-68038-795-7

Attention Deficit Hyperactivity Disorder Market Growth & Trends:

The global attention deficit hyperactivity disorder market size is expected to reach USD 18.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.7% from 2024 to 2030. The presence of a strong product pipeline for the treatment of ADHD and their subsequent approval is expected to boost the market growth. Some late-stage pipeline products are NRCT-101 developed by Neurocentria, Inc., SPN-812 by Supernus Pharmaceuticals, Inc., and EB-1020 by Otsuka America Pharmaceutical, Inc.

Several initiatives undertaken by government bodies regarding early diagnosis and treatment of ADHD are likely to support the market growth. In January 2021, the Australian Government included Vyvanse under its Pharmaceutical Benefits Scheme (PBS) for the treatment of adult patients with ADHD. This inclusion makes the availability of Vyvanse at a subsidized rate to patients and more than 20,000 patients received a comparable treatment for the disease at low cost and benefits. Without PBS subsidy, the patients had to pay more than USD 1,200 per person annually for their treatment. After the inclusion in PBS, they will receive the treatment at USD 41.30 per script. Such initiatives are also expected to drive market growth.

Increasing awareness about ADHD among patients, physicians, and other healthcare providers may increase the demand for diagnosis and treatment which in turn propel the growth of the attention deficit hyperactivity disorder market. The Attention Deficit Hyperactivity Disorder Coaches Organization (ACO) celebrates October as the ADHD awareness month intending to raise awareness, generate funding for R&D, and educate people about disorders. This initiative may boost early diagnosis, thereby, increasing product penetration.

However, the risk of comorbidity with other psychiatric disorders is high among children with ADHD, often making diagnosis and treatment of the disorder complex. A research study published by the Lundbeck Foundation in 2021 showed that ADHD patients with other psychiatric comorbid conditions were more likely to avoid taking medicines. Some of the comorbid conditions that typically occur in ADHD pediatric patients are depression, anxiety, bipolar disorder, learning disorder, early speech/communication problems, and oppositional defiant disorder.

Furthermore, the shortage of stimulants to treat ADHD has forced patients to pay for expensive branded medication and create scope for substitute therapies, such as behavioral therapy, which will negatively impact the demand for ADHD pharmacological therapies. Strict regulations are implemented by regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), which limit the production of ADHD drugs to avoid misuse or abuse. Amid an increase in demand, this can create a shortage of medical products, consequently increasing the cost of treatments and restraining market growth. Thus, the shortage of medicines may impede the market growth.

Attention Deficit Hyperactivity Disorder Market Report Highlights:

  • By drug type, the stimulants segment accounted for the largest share of the market in 2023 due to the high demand for these medicines and the management of symptoms, government support for the use of stimulants drugs, and continuing clinical trials regarding attention deficit hyperactive disorder
  • Based on demographics, the adults segment dominated the attention-deficit hyperactivity disorder market in 2023 owing to the large target population base and high risk of developing the attention-deficit hyperactive disorder. According to ADD Health and Wellness Centers, Inc. the disorder affects approximately 4-5% of the adult population
  • Retail pharmacy segment dominated the attention-deficit hyperactivity disorder market in 2023 and is anticipated to witness the fastest growth over the forecast period. This can be attributed to the wide availability of attention deficit hyperactivity disorder drugs at retail pharmacies and their ease of accessibility to patients
  • North America dominated the global market in 2023 owing to factors such as high awareness among healthcare professionals about drugs available for treatment and the rise in disease prevalence. According to the Center for ADHD Awareness Canada (CADDAC), more than 1.5 million people are affected by the disease in Canad
  • Asia Pacific is expected to be the fastest-growing region during the forecast period to increasing ADHD prevalence and treatment demand in the region. For instance, ADHD is one of the most common neurodevelopment diseases with approximately 8.2% of children and 11% of boys diagnosed in Australia

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug type
    • 1.2.2. Demographics
    • 1.2.3. Distribution channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Chapter 2 Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug type outlook
    • 2.2.2. Demographics outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Attention Deficit Hyperactivity Disorder Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of ADHD
      • 3.2.1.2. Increasing awareness about ADHD Among Physicians And Patients
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Shortage of ADHD drugs
      • 3.2.2.2. Low availability of non-stimulant ADHD drugs
      • 3.2.2.3. Comorbidities leading to underdiagnosis in children
  • 3.3. Attention Deficit Hyperactivity Disorder Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Attention Deficit Hyperactivity Disorder Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Attention Deficit Hyperactivity Disorder Market by Drug Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Stimulants
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Amphetamine
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Methylphenidate
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lisdexamfetamine
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Dexmethylphenidate
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non stimulants
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Atomoxetine
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Guanfacine
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Clonidine
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. Others
      • 4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Attention Deficit Hyperactivity Disorder Market: Demographics Estimates & Trend Analysis

  • 5.1. Demographics Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Attention Deficit Hyperactivity Disorder Market by Demographics Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Children
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Adults
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Distribution Channel Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Attention Deficit Hyperactivity Disorder Market by Distribution Channel Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Hospital pharmacy
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Retail pharmacy
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Attention Deficit Hyperactivity Disorder Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Chapter 8 Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Pfizer, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lupin
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Novartis AG
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Takeda Pharmaceutical Company Limited
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Mallinckrodt plc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Purdue Pharma L.p
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Supernus Pharmaceuticals, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. NEOS Therapeutics, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. H.S. Hospital Service S.p.A.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America attention deficit hyperactivity disorder market, 2018 - 2030 (USD Million)
  • Table 3 North America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 4 North America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 5 North America attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 U.S. attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 8 U.S. attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Canada attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 11 Canada attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Europe attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 14 Europe attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 15 Europe attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Germany attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Germany attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 18 Germany attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 UK attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 UK attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 21 UK attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 France attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 24 France attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Italy attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 Italy attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 27 Italy attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Spain attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Spain attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 30 Spain attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Denmark attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 Denmark attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 33 Denmark attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Sweden attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 Sweden attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 36 Sweden attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Norway attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Norway attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 39 Norway attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Japan attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 45 Japan attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 46 Japan attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 48 China attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 49 China attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 India attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 India attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 52 India attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 South Korea attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 55 South Korea attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Australia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 57 Australia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 58 Australia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 Thailand attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 61 Thailand attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 64 Latin America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 65 Latin America attention deficit hyperactivity disorder n market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Brazil attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 Brazil attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 68 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Mexico attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 73 Mexico attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 74 Mexico attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Argentina attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 76 Argentina attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 77 Argentina attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 MEA Attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 79 MEA attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 80 MEA attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 81 MEA attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Africa attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 South Africa attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 84 South Africa attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 UAE attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 89 UAE attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 90 UAE attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Kuwait attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 92 Kuwait attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 93 Kuwait attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Attention deficit hyperactivity disorder market: Market outlook
  • Fig. 9 Attention deficit hyperactivity disorder market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Attention deficit hyperactivity disorder market driver impact
  • Fig. 14 Attention deficit hyperactivity disorder market restraint impact
  • Fig. 15 Attention deficit hyperactivity disorder market: Drug type movement analysis
  • Fig. 16 Attention deficit hyperactivity disorder market: Drug type outlook and key takeaways
  • Fig. 17 Stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Amphetamine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Methylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Lisdexamfetamine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Dexmethylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Non-stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Atomoxetine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Guanfacine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Clonidine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Attention deficit hyperactivity disorder Market: Demographics movement Analysis
  • Fig. 28 Attention deficit hyperactivity disorder market: Demographics outlook and key takeaways
  • Fig. 29 Children market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Attention deficit hyperactivity disorder market: Distribution channel movement analysis
  • Fig. 32 Attention deficit hyperactivity disorder market: Distribution channel outlook and key takeaways
  • Fig. 33 Hospital pharmacy; market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Global attention deficit hyperactivity disorder market: Regional movement analysis
  • Fig. 36 Global attention deficit hyperactivity disorder market: Regional outlook and key takeaways
  • Fig. 37 North America
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S.
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Japan
  • Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 China
  • Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 India
  • Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea
  • Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Australia
  • Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Thailand
  • Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America
  • Fig. 76 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil
  • Fig. 78 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico
  • Fig. 80 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa
  • Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Africa
  • Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Saudi Arabia
  • Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 UAE
  • Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Kuwait
  • Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)